Orchid Pharma Limited’s Board of Directors has passed an enabling resolution to explore market opportunities for raising funds up to ₹600 Crores. This potential fundraising can be achieved through various methods including equity shares, convertible debentures, qualified institutions placement, or public issues. The approval aims to explore avenues for strategic growth and operational expansion, subject to necessary regulatory and member approvals.
Orchid Pharma Explores Significant Fundraising
In a significant development for its future growth, the Board of Directors at Orchid Pharma Limited has approved an ‘Enabling Resolution’ to explore avenues for raising substantial capital. The company is considering potential market opportunities for raising funds amounting to up to ₹600 Crores (Rupees Six Hundred Crore Only).
Diverse Fundraising Options Approved
The resolution, passed during a board meeting held on October 20, 2026, allows the company to investigate various fundraising mechanisms. These options include the issuance of equity shares, other eligible securities, or instruments such as fully or partly convertible debentures. Furthermore, the company may consider methods like qualified institutions placement, private placement, public issue of equity shares and/or debt securities, preferential issue, or any other permissible mode. A combination of these methods may also be pursued as deemed appropriate.
Strategic Growth Initiative
This initiative is being undertaken in the best interest of the company and is subject to obtaining all requisite statutory and regulatory approvals, including any necessary approval from the members of Orchid Pharma Limited. The board’s decision underscores a strategic intent to bolster financial resources for potential future expansion, market opportunities, and operational enhancements. The specific details regarding the number of securities or the exact amount will be determined as these exploration efforts progress.
Source: BSE
